Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity

被引:7
作者
Hu, Zexi [1 ,2 ]
Wan, Xiaobo [2 ]
Hao, Rui [3 ]
Zhang, Heng [4 ]
Li, Li [2 ]
Li, Lin [2 ]
Xie, Qiang [5 ]
Wang, Peng [6 ]
Gao, Yibo [7 ,8 ]
Chen, She [2 ]
Wei, Min [3 ]
Luan, Zhidong [9 ]
Zhang, Aiqun [10 ]
Huang, Niu [2 ]
Chen, Liang [11 ]
机构
[1] Beijing Normal Univ, Coll Life Sci, Beijing 100875, Peoples R China
[2] Natl Inst Biol Sci, Beijing 102206, Peoples R China
[3] BeiGene Beijing Co Ltd, Beijing 102206, Peoples R China
[4] Cent Hosp Lishui City, Lishui 323000, Zhejiang, Peoples R China
[5] Fuzhou Pulm Hosp Fujian, Fujian 350008, Peoples R China
[6] Beijing Ditan Hosp, Beijing 100015, Peoples R China
[7] Inst Canc Res, Dept Thorac Surg, Beijing 100021, Peoples R China
[8] Hosp Chinese Acad Med Sci, Beijing 100021, Peoples R China
[9] Liaoning Med Univ, Jinzhou 121001, Liaoning, Peoples R China
[10] 301 Hosp, Gen Hosp Peoples Liberat Army, Beijing 100853, Peoples R China
[11] Natl Inst Biol Sci, Collaborat Innovat Ctr Canc Med, Beijing 102206, Peoples R China
基金
中国国家自然科学基金;
关键词
KINASE DOMAIN; BREAST-CANCER; ERBB2; RECEPTOR; RESISTANCE; MECHANISM; INHIBITOR; LAPATINIB; FORMS; KIT;
D O I
10.1371/journal.pone.0123623
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Amplification, overexpression, and somatic mutation of the HER2 gene have been reported to play a critical role in tumorigenesis of various cancers. The HER2 H878Y mutation was recently reported in 11% of hepatocellular carcinoma (HCC) patients. However, its functional impact on the HER2 protein and its role in tumorigenesis has not been determined. Here, we show that HER2 H878Y is a gain-of-function mutation. Y878 represents a phosphorylation site, and phospho-Y878 interacts with R898 residue to stabilize the active conformation of HER2, thereby enhancing its kinase activity. H878Y mutant is transforming and the transformed cells are sensitive to HER2 kinase inhibitors. Thus, our study reveals the following novel mechanism underlying the tumorigenic function of the HER2 H878Y mutation: the introduction of a tyrosine residue into the kinase activation loop via mutagenesis modulates the conformation of the kinase, thereby enhancing its activity.
引用
收藏
页数:12
相关论文
共 30 条
[1]   Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein [J].
Aertgeerts, Kathleen ;
Skene, Robert ;
Yano, Jason ;
Sang, Bi-Ching ;
Zou, Hua ;
Snell, Gyorgy ;
Jennings, Andy ;
Iwamoto, Keiji ;
Habuka, Noriyuki ;
Hirokawa, Aki ;
Ishikawa, Tomoyasu ;
Tanaka, Toshimasa ;
Miki, Hiroshi ;
Ohta, Yoshikazu ;
Sogabe, Satoshi .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (21) :18756-18765
[2]   A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma [J].
Bekaii-Saab, Tanios ;
Williams, Nita ;
Plass, Christoph ;
Calero, Miguel Villalona ;
Eng, Charis .
BMC CANCER, 2006, 6 (1)
[3]   Phosphoproteomic analysis of Her2/neu signaling and inhibition [J].
Bose, Ron ;
Molina, Henrik ;
Patterson, A. Scott ;
Bitok, John K. ;
Periaswamy, Balamurugan ;
Bader, Joel S. ;
Pandey, Akhilesh ;
Cole, Philip A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (26) :9773-9778
[4]   PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib [J].
Corless, CL ;
Schroeder, A ;
Griffith, D ;
Town, A ;
McGreevey, L ;
Harrell, P ;
Shiraga, S ;
Bainbridge, T ;
Morich, J ;
Heinrich, MC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5357-5364
[5]   Activation of Jak2 catalytic activity requires phosphorylation of Y-1007 in the kinase activation loop [J].
Feng, J ;
Witthuhn, BA ;
Matsuda, T ;
Kohlhuber, F ;
Kerr, IM ;
Ihle, JN .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (05) :2497-2501
[6]  
Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO
[7]  
2-Q
[8]   Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice [J].
Hudis, Clifford A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :39-51
[9]   Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib [J].
Kancha, Rama Krishna ;
von Bubnoff, Nikolas ;
Bartosch, Natalie ;
Peschel, Christian ;
Engh, Richard A. ;
Duyster, Justus .
PLOS ONE, 2011, 6 (10)
[10]   Antitumour effects of PLC-γ1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells [J].
Katterle, Y ;
Brandt, BH ;
Dowdy, SF ;
Niggemann, B ;
Zänker, KS ;
Dittmar, T .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :230-235